ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

Budget Cut Asked By Ford Would Hold Grant Funding To 20%

January 10, 1975

AIDS Biological Specimens Available From NIH

November 22, 1985

In Brief: Peter Fischinger Names NCI Deputy Director; ACR Moves Headquarters To Washington Area

November 8, 1985

New Research Projects Proposed For Immunology

September 30, 1977

PI Defends NCI’s National Lung Screening Trial As “Rigorous” Randomized Trial.

November 3, 2006

Summit Conference Reviews Leads In Leukemia, Lymphoma

January 8, 1982